Trifluoperazine
As of the edition of 20 October 2026, Trifluoperazine is a small molecule: marketed, first approved in 1975 (CA); acts on DRD2, DRD3 and DRD4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Stelazine
- First approved
- 31 December 1975 (CA)
- Approvals on record
- 10 in 2 regions
- Holder of the most recent approval
- GSK; 2 holders in all
- Registered trials
- 3, 1 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Trifluoperazine.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Earlier holder |